DHR

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✓

Return

+1.08%

Status

scored

Maintain DHR at 70-75% benchmark weight with a HOLD rating as the highest-evidence consensus among all five analysts; adopt the neutral analyst's tiered trigger framework with technical entry/exit points ($218.50 upside add, $207 hard stop) and a post-Q3 single-trigger upgrade to Overweight upon first qualified signal (EPS ≥$1.23, margin recovery above 20%, or confirmed close above $226.93). The $225-230 preemptive trim is rejected as negative expected value, and no hedge leg is required given 70-75% sizing already serves as the protective mechanism.

Outcome

✓

Return

-0.47%

Status

scored

Maintain DHR at 70-75% benchmark weight as HOLD—the prior trims have already executed the de-risking the bear case demands, making additional reduction redundant ahead of a binary Q3 catalyst in ~3 weeks. A $208 hard stop preserves the medium-term trend invalidation point (50 SMA at $209.83), with a $212 soft warning level for discretionary trim consideration pre-print.

Outcome

✓

Return

+1.34%

Status

scored

Initiate Overweight positioning with a 30-35% starter position at ~$215 and hard stop at $205, deploying the remaining 65-70% reserve only on confirmed technical triggers (50 SMA test-and-hold above $209.44), a constructive Q3 print maintaining or raising forward $9.30 EPS guidance, or pullback to the 200 SMA zone ($200-202). The 9/29 reflection's lesson against the "hold-reflex" in constructive post-pullback regimes, combined with $5.47B TTM FCF, ~75% recurring revenue, and defensive 0.80 beta, supports directional accumulation despite MACD bearish cross, untested 50 SMA support, and a binary Q3 event ~3 weeks out.

Outcome

✗

Return

-2.53%

Status

scored

Maintain DHR at 70-75% benchmark weight as the position sizing already expresses the required de-risking; scale-in with 1.5% at $215-218 and 1.5-2% at confirmed $209-211 test of the 50 SMA, with hard stop at $203 and optional tactical Nov $205 put (1-2% of position) as event-window insurance through the Q3 binary catalyst in 4-6 weeks.

Outcome

✗

Return

+3.34%

Status

scored

Maintain DHR at 70-75% benchmark weight (Hold rating) with a hard stop at $200.00, avoiding adds at the 50 SMA ($208.45) due to distribution volume imbalance (5.3M selloff vs 3.89M bounce) and aggressive 530 bps margin expansion assumption. Trim 25-33% only on confirmed daily close below $208.45 on >5M volume, with preferred re-entry post-Q3 earnings on confirmation of the $9.30 EPS trajectory. Upgrade to Overweight requires any two of four conditions including Q3 EPS confirmation and MACD bullish crossover; downgrade to Underweight requires any one of four conditions including 200 SMA break below $200.81.

Outcome

✓

Return

+1.09%

Status

scored

All five participants reached consensus to maintain DHR at 70-75% of benchmark weight, rejecting the aggressive add thesis in favor of a defensive framework that treats sizing as the protective lever. The hard stop is set at $195.57 (closing basis), with a costless collar (sell $235 call / buy $190 put) recommended for concentrated positions to define range while preserving Q3 2026 earnings participation.

Outcome

✗

Return

-4.42%

Status

scored

Maintain DHR at 70-75% of benchmark weight with a hard stop at $200 and a constructive pullback add zone at $215-218 on the 10-EMA/VWMA confluence with confirmed reversal candle; new entrants should deploy 40% now, reserve 30% for the pullback zone, and hold 30% for post-Q3 confirmation to reduce binary risk around the mid-to-late October earnings catalyst.

Outcome

✗

Return

-2.02%

Status

scored

Maintain DHR at 70-75% benchmark weight with HOLD rating; do not add fresh capital at $226+ given failed breakout at $227.65 and RSI 71, but prepare scale-in zones at $218-220 (50%) and $207-210 (50%) on confirmed reversals. Hard stop at $206.86 (50 SMA), trailing stop at $220.26 (10 EMA); upgrade to Overweight only on close above $242.80 with volume ≥5M shares or Q3 operating margin recovery to 22%+.

Outcome

✓

Return

-0.54%

Status

scored

DHR maintained at HOLD with 70-75% benchmark weight; no new capital deployment at current $227 price level due to unfavorable 0.53R risk/reward math given RSI 71.27 and price +12.9% above 200 SMA. Half-size entries permitted only on confirmed pullback to Zone B ($218-$220) or full sizing at Zone A ($206-$212); upgrade to Overweight requires any two of four triggers including breakout above $242.80 on volume or Q3 EPS beat at $1.23+.

Outcome

✓

Return

+1.27%

Status

scored

DHR maintains HOLD at 70-75% benchmark weight with a hard stop at $209.68 and a 5-6 week time horizon through the Q3 2026 earnings catalyst in mid-to-late October. The decision reflects binding constraints from prior lessons that prohibit underweighting quality compounders with intact FCF, splitting execution with hedges, and trimming into resistance—the Hold at reduced weight generated consistent alpha from 9/17 through 9/23 and remains the highest-probability-correct response given the unresolved binary catalyst.

Outcome

✓

Return

+0.32%

Status

scored

Maintain DHR at 70-75% benchmark weight with hard stop at $199; the technical setup (RSI 68, MACD bearish divergence, upper Bollinger tag) and unfavorable risk/reward (7% upside to $240 vs 10-11% downside to 200 SMA at $201) argue against adding at current $223.77 price; tactical adds only on confirmed pullback to $210-$205 zone at 1/3 sizing with volume confirmation; Q3 2026 earnings in late October is the binary catalyst that will resolve the integration-accretion versus structural-deterioration question.

Outcome

✓

Return

+1.00%

Status

scored

Maintain DHR at 70-75% of benchmark weight with no additions at the current $221.56 price level (above the $200-211 entry zone) and no trims per binding prior lesson constraints. The stop is set at $209.68 (2x ATR from current price, just below the 10 EMA at $211.93), calibrated for realized volatility. Q3 2026 earnings in mid-to-late October serve as the binary catalyst for validating integration accretion, margin trajectory, and forward EPS above $9.30.

Outcome

✓

Return

+0.21%

Status

scored

Maintain DHR at 70-75% of benchmark weight with a hard stop at $198. Avoid adding above $215 given RSI of 65.93 after a +24-point ramp into Bollinger upper band at $221.61, peak net debt of $22.2B, and unproven $9.8B deal integration — tactical adds only permitted at the $208-$212 corridor (10-EMA/50-SMA/VWAP confluence) at 1/3-normal sizing. Q3'26 earnings in late October is the binary catalyst that must resolve integration accretion before any re-rating.

Outcome

✗

Return

+2.43%

Status

scored

Maintain DHR at ~70-75% of benchmark weight as the highest-conviction response given the 4-6 week catalyst horizon before Q3 earnings, with a tiered 1/3-1/3-1/3 deployment plan: first 1/3 triggered on pullback to $208-210 or breakout above $222 on >8M volume, second 1/3 on confirmed breakout, and final 1/3 reserved for post-Q3 earnings validation. Hard stop at $201 on closing basis to identify structural thesis breakdown without noise whipsaw, while the bear case's 38.5x trailing P/E and goodwill concentration warrant asymmetry-discount but not Underweight given binding constraints against quality compounder shorts.

Outcome

✗

Return

+1.90%

Status

scored

Maintain DHR at 70-75% of benchmark weight with hard stop at $195. The conservative analyst wins the arithmetic dispute: the actual R/R is 0.7:1 to the $216 target, not the 2:1 the aggressive analyst claimed, and reaching the upper target requires a full breakout to $220.97 at the Bollinger upper band. The HOLD is binding due to three converging constraints from prior decisions: no Underweight into quality compounders with intact FCF, no split-the-difference execution with protective puts, and no pre-committing trim zones above current price in weakening names.

Outcome

✓

Return

-0.32%

Status

scored

Maintain DHR at ~70-75% of benchmark weight with $195.00 hard stop on closing basis; do not deploy new capital ahead of Q3 2026 earnings catalyst in late October given unresolved binary integration question and unconfirmed MACD. For new exposure, limit pre-Q3 sizing to ≤50% of intended full position, deploying remainder only on confirmed MACD bullish cross or a pullback to $208-210 zone on the 10 EMA. Sizing IS the protective lever—layering a hedge would recreate the 9/04 split-the-difference failure mode.

Outcome

✓

Return

+1.99%

Status

scored

Maintain DHR at 70-75% of benchmark weight with a hard stop at $199 (below the $200 pivot and lower Bollinger band); upgrade to Overweight requires any two of four triggers (close above $210.26 on >4M volume with MACD histogram turning positive, Q3 margin recovery above 20%, MACD line cross above zero, or credible synergy disclosure), while downgrade to Underweight triggers on any one of four conditions including close below $199 on >5M volume, MACD crossing below zero, Q3 EPS miss >5%, or sustained 50 SMA break with negative MACD for >5 sessions.

Outcome

✓

Return

-0.48%

Status

scored

Maintain DHR at 70-75% benchmark weight with a Hold rating, as the unanimous call across all analysts. The stop loss is set at $201.64 (200 SMA), with three entry triggers for potential adds: constructive 50 SMA retest near $202, flush to $196-198, or confirmed breakout above $218.85 on >4M volume. No hedge leg per the binding lessons, and the upgrade thesis to Overweight requires at least two of three conditions: Q3 EPS in line or better than $1.23 with forward $9.30+ held/revised up, operating margin recovery above 20%, and daily close above $218.85 with MACD positive cross.

Outcome

✗

Return

+3.01%

Status

scored

Maintain DHR at 70-75% of benchmark weight (current position already reflects ~25-30% cumulative trim from prior cycles), with hard stop at $195 on closing basis and no hedge leg per the binding 9/04 lesson against split-the-difference execution. Re-engagement requires either MACD bullish cross with close above $215 on rising volume, or Q3 2026 earnings validating $9.30+ forward EPS with credible integration synergy disclosure — with full weight only when at least two triggers fire.

Outcome

✓

Return

+1.55%

Status

scored

Maintain DHR at ~70-75% of benchmark with no new capital deployment at current ~$200 levels; stop-loss set at $196.85 (lower Bollinger band), re-engage only on confirmed close above $215 with MACD positive cross and post-CPI/FOMC macro clarity. The position sizing serves as the protective lever per the 9/04 lesson against split trim+hedge; Q3 2026 earnings in mid-October is the binary catalyst that will determine whether the 460bps sequential margin compression is transitory or structural. The $196.85 stop sits below the structural support cluster at $199-202, so a close below signals genuine regime change rather than single-session overshoot.

Outcome

✓

Return

-0.19%

Status

scored

Maintain DHR with a 25-30% trim executed at current levels ($200-205) on weakness ahead of the Q3 2026 earnings catalyst in mid-October. No hedge leg—the trim itself is the protective action. Firm stop loss at $197.50 closing basis (Bollinger lower band + structural support cluster). Re-add post-Q3 print using a flexible re-entry framework rather than waiting for a rally to $215+.

Outcome

✗

Return

-2.11%

Status

scored

Maintain core DHR exposure but execute a 15-20% trim at current $209-210 levels to position slightly below neutral weight, with hard stop at $198 (lower Bollinger band). The trim executes now per the DHR-specific lesson that trim zones priced above current price in weakening names fail—the prior cycle's $215-218 trim zone was never reached. No hedge leg per lessons prohibiting split trim+hedge actions and oversized hedges in mid-range setups. Q3 earnings in mid-October is the binary catalyst that will drive re-evaluation to either Overweight (clean beat with margin recovery above 20%) or Sell (miss with continued compression).

Outcome

✓

Return

-0.19%

Status

scored

The unanimous directional call across Research Manager, Trader, Conservative, and Neutral analysts is to maintain DHR at benchmark weight with a 10-15% trim into the $215-218 zone to lock in capital ahead of the Q3 earnings catalyst in late October, then reassess; the Aggressive analyst's ADD recommendation fails three critical stress tests including a mathematically wrong 1:4 risk/reward claim (actual is closer to 1:2.5-3), and no protective hedge is warranted per the 9/02 reflection that mid-range catalyst setups consume more in time-decay than realistic drawdowns extract.

Outcome

–

Return

-1.17%

Status

scored

Trim 35% of DHR exposure at the $208-211 zone to reduce concentration risk heading into the Q3 earnings print while preserving core position for DBS integration optionality; hard stop at $199 with pre-committed full exit if price gaps below $195. Layer catalyst-window hedge using 5-10% notional puts at $190-$195 strike, October expiry, sized to the binary event rather than thesis conviction. Reload requires confirmed close above $215 on rising volume with MACD histogram positive.

Outcome

✓

Return

-1.60%

Status

scored

Analysts unanimously maintain Hold on DHR at $211 given fair value with zero margin of safety ($9.30 forward EPS × 22.7x = $211.11), with the Aggressive analyst's bullish golden cross premise invalidated as the 50 SMA ($201.33) sits below the 200 SMA ($202.32). A small catalyst-window hedge of 5-10% notional puts at $190-$195 strike with October expiry is recommended per the 9/02 lesson, while a hard stop at $195 is non-negotiable and trim targets are set at $220-222 on confirmed continuation.

Outcome

✓

Return

+0.53%

Status

scored

Maintain core DHR position at $209.91 with no incremental capital deployment, but layer a catalyst-window-sized hedge (15-20% notional protection at $200 strike, October expiry) to convert the asymmetric downside the Hold thesis itself is flagging into priced alpha. Stop at $196 on closing basis. Trim trigger at $230-240 only on confirmed continuation above $220 — do not trim into the $215-218 zone that cedes the breakout. Q3 2026 earnings (late October) is the binary catalyst.

Outcome

✓

Return

+1.44%

Status

scored

Maintain DHR core position at $206.93 with no new capital deployment, but layer aggressive protective puts (30-40% notional coverage at $200 strike) to hedge the asymmetric downside from declining momentum (MACD bearish cross, sub-10 EMA close, RSI drop 68→51) and unresolved Q3 binary catalyst six weeks out. Tighten thesis-invalidation stop to $199.50 (50 SMA cluster), with hard floor at $179 (July swing low), while preserving core exposure to participate if the conservative analyst is wrong on the aggressive setup.

Outcome

✓

Return

-3.10%

Status

scored

The unanimous consensus across all three analysts, Research Manager, and Trader is Underweight on DHR at $213.56, recommending a 25–30% trim to retain only 2–3% portfolio exposure with no new capital initiation at current levels. Key triggers for re-evaluation at Q3 earnings include upgrade to Hold on sequential EPS expansion with forward $9.30+ or close above $221 on >4M volume, versus downgrade to Sell on >5% EPS miss with forward cut to $8.00–8.50 or close below $200.

Outcome

✓

Return

-1.16%

Status

scored

Maintain neutral exposure in DHR at current levels with tightened stop discipline ($213.50) and expanded entry framework offering three resolution paths: breakout above $222.59, pullback-and-hold at 10 EMA, or post-Q3 earnings re-evaluation. HOLD is unanimous across all three analysts and validated by prior Underweight experiments (8/18, 8/19) that surrendered alpha in this quality compounder.

Outcome

✓

Return

+0.18%

Status

scored

Analysts unanimously maintain HOLD on DHR at $215.68, preserving core exposure while declining to initiate new positions given unconfirmed golden cross, sequential margin compression, and two binary catalysts ahead. Entry is warranted only on tiered pullbacks ($205-210, $195-200) with strict stops, with 10-15% trimming recommended at $220-222 and a hard thesis-invalidation stop at $202.88.

Outcome

✓

Return

+0.15%

Status

scored

Maintain DHR at neutral weight (~$215) with a tiered scale-in framework anchored to $200 thesis-invalidation stop. No full-size initiation above $210; accept 25% starter at $205-210 with $202.40 stop. Hold framework balances the aggressive analyst's momentum thesis (Q2 EBITDA +37.9% YoY, DBS playbook) against the conservative analyst's valid risks (net margin compression to 13.9%, net debt at $22.2B/2.8x EBITDA, 38x trailing P/E). Q3 2026 earnings in late October is the binary catalyst, with upgrade triggers at $221 breakout on volume and downgrade triggers at $200 close below.

Outcome

✓

Return

-0.28%

Status

scored

Maintain DHR core position at $215.97 with partial covered calls (30-50% of position) at $220-230 strikes to harvest elevated implied volatility while preserving upside participation; new capital waits for Tier-1 entry at $200-205 or Tier-2 at $190-195, with Q3 2026 earnings as the binary catalyst for upgrading to Overweight or downgrading to Underweight.

Outcome

–

Return

+0.40%

Status

scored

Trim 25% of DHR in three tranches (10% at $215, 10% at $218, 5% above $220) to reduce exposure ahead of Q3'26 earnings, with a structural stop at $203 and thesis invalidation at $200. The Underweight rating reflects defensive positioning justified by a 15% sequential EPS decline, 61% net debt increase to $22.2B, and bearish MACD divergence, though the $179 structural floor and $4.33B FCF warrant preserving residual core exposure rather than full exit.

Outcome

✓

Return

-1.71%

Status

scored

Maintain DHR core position unchanged at $218+ with HOLD rating, as 23.5x Forward PE with sequential EPS decline of 15.2% and upper Bollinger band proximity make aggressive adding inappropriate. Execute tiered add strategy on confirmed pullbacks to $200-205 (25% allocation) or $190-195 (25% allocation, requiring peer stabilization), with hard thesis-invalidation stop at $185 on volume and 30-day time-stop-clock for untriggered entries.

Outcome

✓

Return

+1.36%

Status

scored

Maintain DHR core position using 10-EMA at $205.97 as trailing stop and 50-SMA at $194.64 as thesis invalidation; do NOT initiate new exposure at $215.91 above upper Bollinger Band with Q3 earnings binary catalyst 6-9 weeks away. New capital should wait for either a confirmed close above $220.63 on volume ≥4M shares with MACD positive (entry with $201.50 stop), or a controlled pullback into the $201.50-$205.97 zone with stabilization (entry with $194.64 stop). Maximum aggregate exposure capped at 3%.

Outcome

✗

Return

+2.09%

Status

scored

Trim 25-30% of DHR at current $210-215 levels (upper Bollinger Band overbought extension) while maintaining 70-75% core exposure as quality compounder ballast, with $220 as an upside re-evaluation trigger rather than stop loss; genuine stop sits below 200 SMA at $202.31. Redeploy trim proceeds 50% to cash/Treasuries and reserve 50% pending either 200 SMA turn + bioprocessing stabilization or Polymarket December rate-cut probability exceeding 25%.

Outcome

✗

Return

+5.97%

Status

scored

Trim 30-40% of DHR into $202-209 rallies while maintaining a smaller-than-benchmark core position, using a hard stop at $179 and March 2027 $190-strike puts as asymmetric hedges ahead of Q3 earnings as the binary catalyst in late October.

Outcome

✓

Return

-1.51%

Status

scored

DHR earns a Hold rating given symmetric 1.8:1 risk/reward that prevents directional conviction either way, despite genuine quality franchise characteristics (Diagnostics moat, $5B FCF) preventing Underweight and multiple headwinds (gross margin at 57.6%, net debt +73.7% QoQ) preventing Overweight. Active position management requires mechanical triggers—a breakout above $213.72 on >4M volume or pullback to $197-200 with RSI above 45 for 25% scale-in tranches—rather than passive drift, with Q3 earnings in late October serving as the binary re-evaluation catalyst.

Outcome

✗

Return

+0.09%

Status

scored

Trim Danaher (DHR) by 30-50% of target weight into any relief rally toward $207-212 rather than waiting for a perfect exit; maintain a smaller core position to preserve long-term compounding exposure. Hard re-evaluation at Q3 earnings in late October, with $179 as the structural floor triggering full exit consideration and March 2027 $190-strike puts recommended as a hedge for concentrated positions.

Outcome

✓

Return

-0.71%

Status

scored

Maintain DHR at neutral with Hold rating; primary stop at $192.38 with a $195 warning trigger where half the position is cut on rising volume, full exit at $192.38. Re-engage on close above $209.37 with volume ≥3M shares, or on successful retest of $197–$200 with RSI reset toward 50 and MACD histogram rebuilding. Q3 2026 earnings in late October is the fundamental catalyst that determines whether the integration thesis holds or breaks.

Outcome

✓

Return

-0.92%

Status

scored

Maintain DHR position at current size; do not add at $205.79. The directional debate produced a clear consensus among the conservative and neutral analysts (and the trader's proposal) that HOLD is the correctly calibrated stance, and the aggressive analyst's bullish case—while containing valid structural arguments—cannot overcome the convergence of unresolved near-term headwinds.

Outcome

✗

Return

-0.80%

Status

scored

Maintain Overweight on DHR with a 10-15% pilot position initiated near $207, holding 85-90% of target weight in reserve for two defined entry triggers: confirmed close above $210 on >3M volume (40% of target allocation) and pullback to $197-202 zone (60% of target). Hard stop set at $199.50, risking approximately 0.5% of capital; full position awaits confirmation rather than chasing resistance amid unresolved leverage, integration drag, and CPI catalyst risks.

Outcome

✓

Return

-0.92%

Status

scored

Maintain DHR at Hold with no new exposure at $209, as the risk-reward at current levels does not justify entry—entry at $209 with stop at $190.79 yields only 1:6 risk to first resistance at $212.16, and the realistic path to $241 requires clearing that resistance. Two defined re-engagement triggers are established: a pullback to $200-197 with 10 EMA support holding, or a breakout above $212.16 on volume exceeding 5M shares, each warranting a 1-2% portfolio add with a hard stop at $190.79; position cap is set at 3-4% of portfolio. The neutral analyst's two-trigger framework is adopted to balance the unresolved tail risks (undisclosed July 21 gap-down cause, $8B+ acquisition with no synergy schedule, goodwill at 74% of assets, forward EPS 65% above trailing against -19.4% three-year CAGR) while preserving participation in the constructive momentum and Montgomery succession thesis.

Outcome

✗

Return

+2.25%

Status

scored

Underweight rating on DHR calls for trimming to 50-60% of benchmark weight (toward the lighter end) given an 11% single-day crash following a "beat-and-raise" quarter, with revenue growth of only +5.5% masking acquisition-accounting EPS optics; sell rallies into $207-$209 rather than waiting for $210.64 Bollinger resistance, set stop at $213 (~1.2x ATR), and hedge 30-40% of remaining position with March 2027 $190-strike puts. Re-evaluate toward Hold/Overweight only on clean breakout above $210.64 on >5M volume, confirmed Q3 bioprocessing reacceleration, or credible CEO strategic vision on October 1.